Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

41.25

Mkt cap

268B

Volume

150K

High

41.57

P/E Ratio

22.63

52-wk high

42.43

Low

41.17

Div yield

0.03

52-wk low

29.20

Roche has introduced a new sequencing technology called sequencing by expansion (SBX), which promises ultra-rapid, high-throughput sequencing. This innovation could significantly impact the next-generation sequencing market.

Portfolio Pulse from

February 20, 2025 | 6:45 pm

The FDA has approved Genentech's Evrysdi tablet, the first and only tablet for treating spinal muscular atrophy (SMA). This approval marks a significant advancement as Evrysdi is the only non-invasive disease-modifying treatment for SMA.

Portfolio Pulse from

February 12, 2025 | 5:00 pm

The FDA has approved Roche's Evrysdi tablet, making it the first and only tablet for treating Spinal Muscular Atrophy (SMA). This approval marks a significant advancement as Evrysdi is a non-invasive, disease-modifying treatment for SMA.

Portfolio Pulse from

February 12, 2025 | 5:00 pm

Genentech's Gazyva shows significant improvement in treating active lupus nephritis, according to a Phase III trial published in the New England Journal of Medicine.

Portfolio Pulse from

February 07, 2025 | 9:00 am

Roche's Gazyva/Gazyvaro shows significant improvement in treating lupus nephritis, as published in the New England Journal of Medicine. The phase III REGENCY trial demonstrated a higher complete renal response rate compared to standard therapy.

Portfolio Pulse from

February 07, 2025 | 9:00 am

The FDA has approved Genentech's Susvimo as the first continuous delivery treatment for diabetic macular edema, a major cause of vision loss in adults with diabetes. This approval marks a significant advancement in treatment options for over 29 million affected individuals worldwide.

Portfolio Pulse from

February 04, 2025 | 5:00 pm

The FDA has approved Roche's Susvimo as the first continuous delivery treatment for diabetic macular edema, a major cause of blindness in adults with diabetes. This approval marks a significant advancement in treatment options, potentially reducing the frequency of eye injections for patients.

Portfolio Pulse from

February 04, 2025 | 5:00 pm

Roche Holding AG reported a strong Q4 and full-year 2024 performance with a ~7% increase in sales and double-digit growth in core EPS. The company has 16 blockbuster drugs, but some face upcoming patent expirations. There was limited information on the progress of their GLP-1 agonist assets.

Portfolio Pulse from

January 31, 2025 | 6:15 pm

Roche has received FDA approval for a label expansion of its PATHWAY anti-HER2/neu diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU treatment. ENHERTU is developed by Daiichi Sankyo and AstraZeneca.

Portfolio Pulse from

January 31, 2025 | 5:00 pm

Roche Holding AG held its Q4 2024 earnings call, discussing financial results and company performance. Key executives participated, and the call included questions from major financial institutions.

Portfolio Pulse from

January 30, 2025 | 7:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.